Vyome Holdings, Inc. Releases VT-1953 Market Assessment; Files 8-K

What Happened
Vyome Holdings, Inc. (HIND) filed a Current Report on Form 8-K on January 28, 2026 to disclose that it is furnishing investor presentation materials under Regulation FD (Exhibit 99.1). The company also issued a press release on January 27, 2026 announcing key findings from an independent U.S. market assessment, commercial forecast, and valuation analysis of VT-1953, Vyome’s lead clinical candidate for treating symptoms of malignant fungating wounds (MFW). The presentation and press release are incorporated by reference into the 8-K (Exhibits 99.1 and 99.2).

Key Details

• 8-K filed January 28, 2026; press release issued January 27, 2026.
• Exhibit 99.1: Product Assessment and Valuation Report (investor presentation materials furnished under Regulation FD).
• Exhibit 99.2: Press release summarizing independent U.S. market assessment, commercial forecast, and valuation for VT-1953.
• VT-1953 identified as Vyome’s lead clinical candidate for treatment of symptoms of malignant fungating wounds (MFW).

Why It Matters
This disclosure gives investors access to independent commercial and valuation information about VT-1953, which can inform views on the drug’s market potential and Vyome’s development strategy. Furnishing the presentation under Regulation FD signals the company is sharing material commercial analysis publicly rather than selectively, improving transparency. The filing does not report financial results or corporate changes; investors should review Exhibits 99.1 and 99.2 for the detailed assessment and forecasts.